#ERS26: Roivant reports Phase 2 win for lung disease drug that it got from Bayer

Phase 2positivemosliciguatPositive

AI Analysis

Summary

Roivant Sciences reported positive Phase 2 trial results for mosliciguat, an inhaled drug candidate acquired from Bayer, demonstrating efficacy in interstitial lung disease and exceeding Wall Street expectations.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Met primary endpoint of change in interstitial lung disease trial, surpassed Wall Street benchmarks

Importance:7/10

Sentiment:

0.85

Phase 2positive datainhaled druginterstitial lung diseaseBayer asset

Related Companies

$BAYRY

Read the original article

Published by Endpoints News on September 8, 2026 10:00 AM

Read Original